Navigation Links
Neuralstem Receives Notice of Patent Allowance for Spinal Cord Delivery Platform
Date:10/12/2011

h its cell therapy platform, including spinal cord injury, ischemic spastic paraplegia, chronic stroke, and Huntington's disease. The company has submitted an IND (Investigational New Drug) application to the FDA for a Phase I safety trial in chronic spinal cord injury.

Neuralstem also has the ability to generate stable human neural stem cell lines suitable for the systematic screening of large chemical libraries. Through this proprietary screening technology, Neuralstem has discovered and patented compounds that may stimulate the brain's capacity to generate new neurons, possibly reversing the pathologies of some central nervous system conditions.  Neuralstem's first small molecule compound, NSI-189 is currently in a Phase I FDA-approved safety trial in major depressive disorder.  The Phase Ib portion of the trial, in depressed patients, is expected to commence later this year. Additional indications could include schizophrenia, Alzheimer's disease and bipolar disorder.

For up-to-date information on the clinical trial for ALS and other Neuralstem cell therapy and pharmaceutical treatments in development, visit www.neuralstem.com

Cautionary Statement Regarding Forward Looking Information

This news release may contain forward-looking statements made pursuant to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Investors are cautioned that such forward-looking statements in this press release regarding potential applications of Neuralstem's technologies constitute forward-looking statements that involve risks and uncertainties, including, without limitation, risks inherent in the development and commercialization of potential products, uncertainty of clinical trial results or regulatory approvals or clearances, need for future capital, dependence upon collaborators and maintenance of our intellectual property rights. Actual results may differ ma
'/>"/>

SOURCE Neuralstem, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Neuralstem President and CEO to Present at the 2011 Stifel Nicolaus Annual Healthcare Conference
2. Neuralstem Awarded Department of Defense Contract for Brain Cancer Research
3. Neuralstem Reports First Quarter Financial Results and Provides Business and Clinical Update
4. Former Capital One Director and Business Leader Stanley I. Westreich Joins Neuralstems Board
5. Neuralstem, Inc. Settles Litigation Against ReNeuron, Ltd.
6. Neuralstem, Inc. to Present At World Stem Cells and Regenerative Medicine Congress
7. Neuralstem Completes $5.25 Million Financing
8. Neuralstem, Inc. Reports Third Quarter Financial Results and Provides Business Update
9. Neuralstem Receives FDA Approval to Commence First ALS Stem Cell Trial
10. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Neuralstem, Inc.
11. Neuralstem to Present at the 11th Annual BIO CEO & Investor Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... 15, 2014 Freeslate, Inc ... solutions, today announced that Lupin Limited, one of ... of Freeslate’s CM Protégé PharmD System ... Lupin, headquartered in Mumbai, India, is focused on ... branded formulations and Active Pharmaceutical Ingredients (APIs) for ...
(Date:1/14/2014)... San Diego, CA (PRWEB) January 14, 2014 ... developing solutions based on the products of cells ... they have entered into an international license agreement ... containing Histogen’s proprietary multipotent cell conditioned media (CCM). ... to the existing license between Histogen and Suneva ...
(Date:1/14/2014)... and BETHESDA, Md. , Jan. ... are joining together with two institutes from the ... develop more reliable tools for bringing safer, more ... Organovo is collaborating with the National Center for ... Institute (NEI) to develop better and more clinically ...
(Date:1/14/2014)... , Jan. 14, 2014   Kinaxis ®, ... management ( SCM ) and sales and operations planning ... gold sponsor of the Biomanufacturing Summit , which ... January 30 – 31, 2014.  At the conference, join ... Chain at Amgen, as she presents ,Supply Chain: Improving ...
Breaking Biology Technology:Lupin Selects Freeslate’s CM Protégé PharmD System to Accelerate Polymorph Screening for Drug Development 2Lupin Selects Freeslate’s CM Protégé PharmD System to Accelerate Polymorph Screening for Drug Development 3Histogen and Suneva Medical Expand License for Cell Conditioned Media-based Aesthetic Products Internationally 2Histogen and Suneva Medical Expand License for Cell Conditioned Media-based Aesthetic Products Internationally 3Organovo Announces Collaboration with National Institutes of Health 2Organovo Announces Collaboration with National Institutes of Health 3Event Alert: Kinaxis Customer to Present at the Biomanufacturing Summit "Supply Chain: Improving Network Effectiveness" 2
... Scientific,Corporation (NYSE: BSX ) is scheduled to participate ... being held September 10 and 11,in New York City. ... make a,25-minute presentation followed by a 25-minute question and ... a.m. ET. A live webcast of Mr. LaViolette,s ...
... Artery ... Disease - ... -, FREMONT, Calif., Aug. 28 Vermillion, Inc.,(Nasdaq: VRML ), formerly ... called beta-2,microglobulin may aid in the diagnosis of peripheral artery disease (PAD).,The findings, ...
... (Pink Sheets: BIEL), announced today that Astonix Life,Science, ... provide ActiPatch,Therapy to the healthcare market in Singapore. ... ActiPatch to the market has been warmly,received. ... the Healthcare providers,in Singapore has been strong enough ...
Cached Biology Technology:Vermillion and Collaborators Discover Protein Biomarker Associated with Peripheral Artery Disease 2Vermillion and Collaborators Discover Protein Biomarker Associated with Peripheral Artery Disease 3BioElectronics Corporation Announces Singapore and Malaysia Sales 2
(Date:4/14/2014)... of subarctic forest moths in Finnish Lapland suggests that ... on animals and plants because much of the harm ... of 80 moth species and found that 90 percent ... study period, from 1978 to 2009. During that time, ... degrees Fahrenheit, and winter precipitation increased as well. , ...
(Date:4/14/2014)... climate over the past three decades have caused small ... national animal. UCLA biologists have found that not only ... has also become shorter and higher pitched. ... integrative biology and physiology and of ecology and evolutionary ... study examined 170 male coqui frogs ( Eleutherodactylus coqui ...
(Date:4/14/2014)... ( http://www.ucr.edu ) David Kisailus, the Winston ... University of California, Riverside,s Bourns College of Engineering, ... Fellows are young scientists selected by the advisory ... National Academy of Sciences and organizers of the ... series. The Kavli Foundation, which is based in ...
Breaking Biology News(10 mins):Moth study suggests hidden climate change impacts 2Moth study suggests hidden climate change impacts 3Climate change a likely culprit in coqui frog's altered calls, say UCLA biologists 2Professor receives young scientist honor 2
... permanently damaged their skin cells, causing them to overproduce ... uneven skin tone over time. But new research indicates ... arthritis ?can actually help stop the formation of new ... findings on glucosamine may impact the way dermatologists treat ...
... warm, sun-drenched, tropical seas; some species are found at ... waters throughout the world's oceans. Some cold-water coral reefs ... a diversity rivaling some better known tropical coral reefs. ... method in which vessels drag large, heavily weighted nets ...
... the rewarding effect of cocaine on mice by genetically ... animal's brain. , While the researchers aren't suggesting that ... brings to light the key protein that controls cocaine's ... medications that achieve the same results and therefore help ...
Cached Biology News:Science finds new fix for UV-damaged skin in arthritis treatment 2Science finds new fix for UV-damaged skin in arthritis treatment 3Ocean acidification threatens cold-water coral ecosystems 2Genetically altered mice no longer like cocaine 2Genetically altered mice no longer like cocaine 3
Human Apolipoprotein B100 Affinity Purified Polyclonal Ab ENTREZ GeneID: 338...
hypertension-related calcium-regulated gene, mRNA...
Human PLUNC MAb (Clone 252512)...
... GRASP1 ( Abpromise for all ... Synthetic peptide corresponding to amino ... region of rat GRASP1, conjugated to ... Entrez GeneID: 56850 ...
Biology Products: